First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors

BACKGROUND: We conducted a first-in-human dose-escalation study with the oral FASN inhibitor TVB-2640 to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D), as monotherapy and with a taxane. METHODS: This completed open-label outpatient study was conducted at 11 sites in...

Descripción completa

Detalles Bibliográficos
Autores principales: Falchook, Gerald, Infante, Jeffrey, Arkenau, Hendrik-Tobias, Patel, Manish R., Dean, Emma, Borazanci, Erkut, Brenner, Andrew, Cook, Natalie, Lopez, Juanita, Pant, Shubham, Frankel, Arthur, Schmid, Peter, Moore, Kathleen, McCulloch, William, Grimmer, Katharine, O'Farrell, Marie, Kemble, George, Burris, Howard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8040281/
https://www.ncbi.nlm.nih.gov/pubmed/33870151
http://dx.doi.org/10.1016/j.eclinm.2021.100797

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8040281/
https://www.ncbi.nlm.nih.gov/pubmed/33870151
http://dx.doi.org/10.1016/j.eclinm.2021.100797

Ejemplares similares